Inquiry Basket
BOC Sciences offers comprehensive one-stop antibody-drug conjugate research and evaluation services.
BOC Sciences provides customers with comprehensive one-stop services for all aspects of antibody-drug conjugate research and evaluation, from antibody modification and conjugation, cytotoxin development, cytotoxin-linker synthesis, ADC manufacturing, to ADC characterization and evaluation various stages.
Jun 29, 2024
Kadcyla, also known as Trastuzumab Emtansine, is a breakthrough drug for the treatment of breast cancer. This innovative drug is a targeted therapy that combines the efficacy of two well-known anticancer drugs, Trastuzumab and Emtansine, to specifically target and destroy cancer cells that overexpress human epidermal growth factor receptor 2 (HER2).
Jun 2, 2024
To date, the FDA has approved a total of 14 antibody drug conjugates (ADCs) for various cancer indications. These drugs specifically target cancer cells, delivering powerful chemotherapy drugs directly to tumors while minimizing damage to healthy tissue.
